Company intelligence / Profile preview
Alkahest, Inc.
San Carlos, California, United States
- Ownership
- Private
- Employees
- ~82
- Development stage
- Phase 2
01
Overview
Alkahest has completed multiple Phase 1 and 2 studies for its candidate therapeutics GRF6019 and AKST4290. GRF6019 showed positive top-line data in a Phase 2 trial for mild-to-moderate Alzheimer's disease, demonstrating safety and tolerability. The company has several ongoing clinical trials for various age-related conditions[7][9].
- Therapeutic areas
- OtherOphthalmologyImmunologyNeurology
- Modalities
- Plasma fractionssmall moleculesprotein-targeted interventions
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
GrifolsMichael J. Fox FoundationBiogen
Beyond the preview
Go deeper on Alkahest, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alkahest, Inc..